crossover design when use ABEL with two test products [Design Issues]

posted by BEQool  – 2024-02-22 10:15 (450 d 16:10 ago) – Posting: # 23870
Views: 3,365

Hello,
so the most appropriate design for 2 test treatments and replicated reference is a below one?

T1  R   T2   R

R   T1  R   T2

T2  R   T1  R

R   T2  R   T1


Do you think EMA regulators would have any objections if this is was pivotal study (of course bearing Bonferroni adjustment in mind)?

Probably following designs would be worse?:

a) EMA suggested replicate design with additional test treatment
TRR|T2
RTR|T2
RRT|T2


b) 3x6x3 Williams design with additional reference treatment
ABC|C
ACB|C
BAC|C
BCA|C
CAB|C
CBA|C


Best regards
BEQool

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,673 registered users;
150 visitors (0 registered, 150 guests [including 13 identified bots]).
Forum time: 03:25 CEST (Europe/Vienna)

Nothing shocks me. I’m a scientist.    Harrison Ford (as Indiana Jones)

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5